S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:ARAY

Accuray (ARAY) Stock Price, News & Analysis

$2.47
+0.04 (+1.65%)
(As of 03/28/2024 ET)
Today's Range
$2.43
$2.51
50-Day Range
$2.37
$2.94
52-Week Range
$2.36
$4.30
Volume
423,690 shs
Average Volume
483,438 shs
Market Capitalization
$244.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25

Accuray MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
234.0% Upside
$8.25 Price Target
Short Interest
Bearish
5.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.60mentions of Accuray in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$44,511 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.07) to $0.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.93 out of 5 stars

Medical Sector

241st out of 939 stocks

Surgical & Medical Instruments Industry

30th out of 97 stocks

ARAY stock logo

About Accuray Stock (NASDAQ:ARAY)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

ARAY Stock Price History

ARAY Stock News Headlines

Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
ARAY Apr 2024 4.000 call
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
7 Screaming Stock Buys for Under $5
ARAY Mar 2024 2.000 call
ARAY Mar 2024 2.000 put
Q2 2024 Accuray Inc Earnings Call
Recap: Accuray Q2 Earnings
Accuray Incorporated Q2 Loss increases, misses estimates
Accuray: Fiscal Q2 Earnings Snapshot
See More Headlines
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
3/29/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
1,024
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$8.25
High Stock Price Target
$9.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+234.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-9,280,000.00
Pretax Margin
-2.38%

Debt

Sales & Book Value

Annual Sales
$447.61 million
Book Value
$0.56 per share

Miscellaneous

Free Float
95,420,000
Market Cap
$244.95 million
Optionable
Optionable
Beta
1.44

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


ARAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Accuray stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings
or view top-rated stocks.

What is Accuray's stock price target for 2024?

3 brokerages have issued 1 year target prices for Accuray's shares. Their ARAY share price targets range from $7.50 to $9.00. On average, they predict the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 234.0% from the stock's current price.
View analysts price targets for ARAY
or view top-rated stocks among Wall Street analysts.

How have ARAY shares performed in 2024?

Accuray's stock was trading at $2.83 at the beginning of the year. Since then, ARAY stock has decreased by 12.7% and is now trading at $2.47.
View the best growth stocks for 2024 here
.

Are investors shorting Accuray?

Accuray saw a increase in short interest in March. As of March 15th, there was short interest totaling 5,420,000 shares, an increase of 5.9% from the February 29th total of 5,120,000 shares. Based on an average trading volume of 417,700 shares, the days-to-cover ratio is currently 13.0 days.
View Accuray's Short Interest
.

When is Accuray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ARAY earnings forecast
.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) announced its quarterly earnings data on Wednesday, January, 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The medical equipment provider had revenue of $107.24 million for the quarter, compared to analyst estimates of $107.11 million. Accuray had a negative trailing twelve-month return on equity of 28.11% and a negative net margin of 3.25%. During the same quarter in the previous year, the firm earned ($0.02) EPS.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2024 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $460.0 million-$470.0 million, compared to the consensus revenue estimate of $463.0 million.

What is Joshua Levine's approval rating as Accuray's CEO?

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.31%), Vanguard Group Inc. (5.31%), Heartland Advisors Inc. (2.94%), Wellington Management Group LLP (1.84%), Dimensional Fund Advisors LP (1.84%) and Foundry Partners LLC (1.51%). Insiders that own company stock include Ali Pervaiz, Brandon W Green, Byron C Scott, Gina Corradetti, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Sandeep Chalke and Suzanne C Winter.
View institutional ownership trends
.

How do I buy shares of Accuray?

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Accuray have any subsidiaries?
The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More
This page (NASDAQ:ARAY) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners